Physician profile
Barbara M Lee
NPI 1649237124
$1,197.52
in general payments reported to CMS, 2019-2025
10 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $39.86 · 2021: $197 · 2022: $36.93 · 2024: $206 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $421.28 | 2019-2025 | Clareon, Argos |
| Tarsus Pharmaceuticals, INC. | $269.70 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $136.42 | 2019-2021 | |
| Abbvie INC. | $114.32 | 2024-2025 | |
| Kala Pharmaceuticals, INC. | $112.29 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $37.66 | 2025 | Vyzulta, Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $33.63 | 2021 | |
| Optinose US, INC. | $29.55 | 2019-2020 | |
| Harrow Eye, LLC | $25.08 | 2025 | Vevye |
| Regeneron Healthcare Solutions, INC. | $17.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.